CA2185661A1 - Novel iron chelator and inhibitor of iron-mediated oxidation - Google Patents

Novel iron chelator and inhibitor of iron-mediated oxidation

Info

Publication number
CA2185661A1
CA2185661A1 CA002185661A CA2185661A CA2185661A1 CA 2185661 A1 CA2185661 A1 CA 2185661A1 CA 002185661 A CA002185661 A CA 002185661A CA 2185661 A CA2185661 A CA 2185661A CA 2185661 A1 CA2185661 A1 CA 2185661A1
Authority
CA
Canada
Prior art keywords
iron
exochelins
inhibitor
novel
mediated oxidation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185661A
Other languages
French (fr)
Other versions
CA2185661C (en
Inventor
Lawrence Horwitz
Marcus A. Horwitz
Bradford W. Gibson
Joseph Reeve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Lawrence Horwitz
Marcus A. Horwitz
Bradford W. Gibson
Joseph Reeve
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/383,180 external-priority patent/US5721209A/en
Application filed by Lawrence Horwitz, Marcus A. Horwitz, Bradford W. Gibson, Joseph Reeve, The Regents Of The University Of California filed Critical Lawrence Horwitz
Publication of CA2185661A1 publication Critical patent/CA2185661A1/en
Application granted granted Critical
Publication of CA2185661C publication Critical patent/CA2185661C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Exochelins can be used to prevent damage to living tissue from the formation or presence of the (OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins at well as other applications of these materials in the treatment and diagnosis of disease in mammals.
CA002185661A 1995-02-03 1996-01-26 Novel iron chelator and inhibitor of iron-mediated oxidation Expired - Fee Related CA2185661C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/383,180 1995-02-03
US08/383,180 US5721209A (en) 1995-02-03 1995-02-03 Iron chelator and inhibitor of iron-mediated oxidant injury
PCT/IB1996/000171 WO1996023502A1 (en) 1995-02-03 1996-01-26 Novel iron chelator as inhibitor of iron-mediated oxidation

Publications (2)

Publication Number Publication Date
CA2185661A1 true CA2185661A1 (en) 1996-08-08
CA2185661C CA2185661C (en) 2005-10-04

Family

ID=35395857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185661A Expired - Fee Related CA2185661C (en) 1995-02-03 1996-01-26 Novel iron chelator and inhibitor of iron-mediated oxidation

Country Status (1)

Country Link
CA (1) CA2185661C (en)

Also Published As

Publication number Publication date
CA2185661C (en) 2005-10-04

Similar Documents

Publication Publication Date Title
BG103438A (en) Improvements of or in relation to diagnostic/therapeutical forms
AU4674496A (en) Novel iron chelator and inhibitor of iron-mediated oxidation
CA2180950A1 (en) Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
WO2000041707A3 (en) USE OF $i(LACTOBACILLUS SALIVARIUS)
MY119778A (en) Androstenone derivative.
BR9902243A (en) Biomedical devices with hydrophilic coatings
EP2348032A3 (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
FR2782269B1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING SALICYLIC ACID OR A SALICYLIC ACID DERIVATIVE AND USE THEREOF
SE8903914D0 (en) ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
OA08617A (en) Neutral metalloendopeptidase inhibitors in the treatment of hypertention.
IT1224733B (en) BACTERIAL TREATMENT TO PRESERVE HAY QUALITY THROUGH THE ADDITION OF MICROORGANISMS OF THE GENDER BACILLUS
FR2378523A1 (en) ACNE TREATMENT MEDICINE
JPS57128634A (en) Elastase-containing compound increasing absorption
FR2718639B1 (en) Cosmetic and / or dermatological composition containing a tri (alpha-hydroxyacylate) of glycerol as the only precursor of glycerol.
HUP0001014A2 (en) Use of gastrointestinal lipase inhibitors
CA2271162A1 (en) Stearidonic acid compositions and uses thereof
ATE374618T1 (en) USE OF RECOMBINANT HUMAN UTEROGLOBIN FOR THE TREATMENT OF FIBROTIC DISEASES
ES2145302T3 (en) WHITENING AGENT.
ATE211908T1 (en) INTRAVENOUS SOLUTION THAT REDUCES PROTEIN AND WATER LOSS IN THE BODY
CA2304564A1 (en) Basket with one or more moveable legs
CA2185661A1 (en) Novel iron chelator and inhibitor of iron-mediated oxidation
CA2246236A1 (en) Treatment and prevention of adverse effects of reactive oxygen species
CA2241825A1 (en) New monofunctionalized edta, dtpa and ttha derivatives and their use in medical diagnosis and therapy
IT8721999A0 (en) PROCEDURE FOR THE MANUFACTURE OF FLOOR OR WALL COATINGS WHICH PRESENT IMPROVED RESISTANCE TO SOILING AND THE PRODUCT OBTAINED.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed